NMN and NR Safety in Adults 65 and Older: What the Evidence Actually Shows

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are both precursors to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in cellular energy metabolism and DNA repair. Neither compound is an FDA-approved drug. Both are sold in the United States as dietary supplements, meaning they do not go through the premarket safety and efficacy review required of prescription medications. NMN and NR are chemically distinct but converge on the same metabolic pathway, and both are marketed heavily to adults over 65 as "anti-aging" or "energy" products.

No randomized controlled trial has enrolled a cohort of adults 65 or older specifically to evaluate the safety of NMN or NR. The best available human data come from short trials, generally 6 to 10 weeks, in healthy or metabolically mild middle-aged and older adults, at doses up to roughly 1,000 to 1,250 mg per day. Those trials were not designed or powered to detect the safety problems that matter most in geriatric medicine: renal clearance changes, drug interactions in patients on multiple medications, and orthostatic effects that raise fall risk. As of 2026, whether NMN or NR is safe for a 78-year-old on anticoagulants, antihypertensives, or with reduced kidney function is not established by published evidence.

Why this matters for adults 65 and older specifically

NAD+ levels fall with age, and that decline is biologically plausible as a contributor to age-related changes in mitochondrial and metabolic function. Preclinical work in aged mice given NMN has reported improvements in glucose handling and mitochondrial markers. That mouse data is genuinely part of the scientific rationale for human interest in NAD+ precursors, but mice do not have the renal function, hepatic blood flow, or medication lists of a typical geriatric patient, and preclinical rodent findings do not establish human safety or dosing.

The practical question for an older adult or their clinician is not whether NAD+ decline is real, or whether NMN and NR raise NAD+ levels in humans over weeks. Short trials support both of those points. The real question is whether raising NAD+ through supplementation is safe in a body with reduced kidney clearance, reduced hepatic blood flow, and several other medications already in circulation. That question has not been directly tested.

What the human trials show, and what they leave out

A small number of published human trials have tested NMN or NR, generally in healthy or metabolically mild adults, over periods of 6 to 10 weeks. Reported findings across this body of work include modest increases in blood or plasma NAD+ metabolites, and in at least one trial, improved measures of insulin sensitivity in postmenopausal women in their late fifties. One NR trial appears to have enrolled a cohort with a mean age close to 65, which is the closest any published study has come to a geriatric population, but it involved a small number of participants over a short duration.

None of these trials was designed to detect the adverse events that matter most in older adults: changes in kidney function over months to years, interactions with common cardiovascular or diabetes medications, falls related to blood pressure changes, or cumulative effects on nutrient status. Short-term tolerability in a healthy 55-year-old does not translate directly to safety in a frail 82-year-old on five medications. This is not a criticism of the existing trials, which answered the questions they were designed to answer. It is a statement about what those trials cannot tell a geriatric patient.

Note on sourcing: the specific trial identifiers, sample sizes, and numeric effect sizes commonly cited for these studies could not be independently verified for this draft and should be confirmed against the primary literature (PubMed, ClinicalTrials.gov, or the original journal) before being used to support any specific clinical recommendation or dosing decision.

What is established, what is plausible, and what is not established

Established: NMN and NR are metabolized through the NAD+ salvage pathway and raise measurable NAD+-related metabolites in blood after weeks of use in human trials. Neither compound has FDA approval as a drug. Age-related decline in glomerular filtration rate is a well-recognized feature of normal aging.

Plausible but unproven: That reduced renal clearance in older adults could lead to accumulation of nicotinamide-derived metabolites during chronic NMN or NR use. That reduced hepatic blood flow and enzyme activity with age could slow conversion of NMN or NR to NAD+, altering the amount of unconverted precursor available for renal clearance. That NR's reported blood-pressure-lowering effect in younger and middle-aged adults could produce symptomatic hypotension when added to antihypertensive regimens in older adults.

Not established: Any specific safe dose of NMN or NR for adults 65 and older. Any specific interaction profile with metformin, anticoagulants, statins, or antihypertensives in older adults. Long-term (beyond several months) safety of either compound in any age group.

Renal clearance: the unaddressed geriatric variable

NMN and NR both feed into hepatic nicotinamide metabolism, producing metabolites that are cleared by the kidneys. Glomerular filtration rate tends to decline gradually across adulthood, and by the seventh or eighth decade of life many adults have filtration rates in a range that would qualify as chronic kidney disease stage 3 even without a formal CKD diagnosis. Reduced clearance capacity is one of the most consistent physiologic findings in geriatric medicine.

Niacin (nicotinic acid), a related but chemically distinct NAD+ precursor used at pharmacological doses for lipid management, has been associated with modest rises in serum creatinine and uric acid in some trial populations, and is generally used with caution in patients with impaired kidney function. NMN and NR generate the same downstream nicotinamide metabolites as niacin, through a different upstream route and typically at lower doses than therapeutic niacin regimens. Whether this translates into a meaningful renal signal in older NMN or NR users has not been tested in a published study. No study has prospectively measured serum creatinine, cystatin C, or nicotinamide metabolite accumulation in adults 65 and older taking either compound.

A cautious, clinically grounded approach is to obtain a baseline metabolic panel including estimated GFR before an older adult starts either supplement, and to treat an eGFR below roughly 45 mL/min/1.73m² as a reason to discuss the decision with a physician rather than proceed independently.

Drug interactions in a polypharmacy population

Adults in their late sixties commonly take several prescription medications, and that number tends to rise with age. NMN and NR have essentially no published interaction data in this context. The concerns below are grounded in known biochemistry rather than clinical trial findings, and should be read as reasons for caution and monitoring rather than confirmed risks.

Metformin. Both metformin and NAD+ precursors intersect with AMPK-related metabolic signaling. Whether combining metformin with NMN or NR changes glucose control in either direction has not been studied.

Anticoagulants (warfarin and direct oral anticoagulants). Niacin at pharmacological doses has been linked to modest changes in anticoagulation parameters in some reports. Whether supplement-dose NMN or NR affects bleeding risk or INR has not been tested. Given the consequences of unexpected anticoagulant potentiation in an older adult with fall risk, this gap is clinically relevant even in the absence of confirmed data.

Statins. High-dose nicotinic acid combined with statins has been associated with increased myopathy risk, a concern that has prompted regulatory warnings about niacin-statin combination dosing in the past. NMN and NR generate nicotinamide rather than nicotinic acid, and the myopathy signal in the FDA communication is specific to nicotinic acid formulations, so the mechanism does not directly transfer. Even so, no clinical data confirm the absence of risk for NMN or NR in statin-treated older adults.

Antihypertensives. At least one small trial reported a modest reduction in systolic blood pressure with NR supplementation in middle-aged and older adults. In a patient already on antihypertensive therapy with a normal or low-normal baseline blood pressure, an additive drop could produce dizziness or falls. Orthostatic hypotension is already common in community-dwelling older adults, which raises the stakes of any additional blood-pressure-lowering exposure.

Hepatic metabolism and the aging liver

The liver is the main site of nicotinamide metabolism, and hepatic blood flow and phase I enzyme activity both tend to decline with age. NMN is converted toward NAD+ via the enzyme NMNAT; NR is first converted to NMN by nicotinamide riboside kinases before entering the same step. Whether these conversion steps become rate-limiting in an aging liver with reduced blood flow, and whether that changes how much unconverted precursor reaches the kidneys, is an open question rather than a documented finding. A published review on NAD-targeted therapeutics has noted that the pharmacokinetics of NAD+ precursors in adults over 70 remain a significant knowledge gap; the specific citation for this statement requires verification before it is used as a stand-alone reference.

Gastrointestinal tolerability and nutrient considerations

Mild gastrointestinal symptoms, including nausea, bloating, and loose stools, are the most commonly reported side effects across NMN and NR trials, generally affecting a minority of participants at higher doses. In an older adult with pre-existing GI disease, reduced appetite, or a medication list that already carries GI side effects, an added source of nausea is not a trivial nuisance; it can worsen intake, contribute to unintended weight loss, and compound frailty.

Nicotinamide clearance depends on hepatic methylation, which theoretically could affect methyl-donor status (such as folate and B12-related pathways) with chronic high-dose use. This is a plausible mechanism raised in the pharmacology literature rather than a documented clinical finding in NMN or NR users specifically. It is a reasonable basis for checking homocysteine or B12 status in an older adult with known deficiency risk before starting long-term supplementation, not a reason for alarm on its own.

A risk-stratification framework for adults 65 and older considering NMN or NR

Because no trial defines a safe dose or interaction profile for this age group, the more useful clinical question is not "is NMN safe" but "which older adults carry enough additional risk factors that supplementation should be deferred, supervised, or avoided." The framework below organizes the risk factors discussed above into a decision aid for patients and clinicians. It is a synthesis based on the evidence gaps described in this article, not a validated clinical tool, and it does not replace individualized medical judgment.

How to use this table: a patient who falls in the "higher-concern" column for two or more factors is a reasonable candidate for deferring supplementation until discussed with a physician, or for starting only under structured monitoring with baseline and follow-up labs. A patient with no higher-concern factors still lacks trial-level safety data specific to their age group, but carries fewer of the plausible risk mechanisms described above. This table cannot substitute for a clinician's review of the full medication list and history.

What monitoring could reasonably look like

If an older adult and their physician decide to proceed despite the evidence gaps, a structured approach reduces (without eliminating) the uncertainty:

Before starting: baseline metabolic panel including eGFR, complete blood count, liver function tests, uric acid, and a full medication and supplement review. Consider orthostatic blood pressure measurement (supine and standing).

Early follow-up (around 4 weeks): repeat renal and liver function tests, recheck orthostatic vitals, and ask specifically about nausea, unusual bruising or bleeding, and dizziness.

Ongoing: if no adverse signals appear, monitoring intervals can reasonably extend, with continued attention to eGFR trend. A meaningful decline in eGFR from baseline is a reason to reduce or stop the supplement and reassess with a clinician.

This is a conservative, judgment-based protocol reflecting the absence of trial data, not a guideline-endorsed monitoring schedule. No professional society has published a specific monitoring standard for NMN or NR in geriatric patients as of 2026.

When to seek medical attention rather than self-manage

An older adult taking NMN or NR should contact a clinician promptly, rather than simply stopping and waiting, if they notice new or worsening dizziness on standing, unexplained bruising or bleeding, a marked change in urine output, unexplained nausea that limits eating or drinking, or any new symptom that coincides with starting or increasing the dose. These are general precautions appropriate to an unmonitored supplement rather than findings specific to NMN or NR.

The gap between marketing claims and clinical evidence

NAD+ precursor products are marketed to older adults with language about reversing aging and restoring youthful energy. The underlying biology, that NAD+ declines with age and that restoring it is mechanistically plausible, is a genuine basis for scientific interest. But the distance between an aged mouse regaining metabolic markers after NMN and an older adult on multiple medications safely using NMN long-term is not a small one. That distance is made up of trials that have not been run in this age group, interaction questions that have not been asked, and pharmacokinetic parameters that have not been measured in adults over 70.

The reasonable clinical position is neither to prohibit use outright nor to endorse it without qualification. NMN and NR are biologically active compounds with plausible mechanisms of both benefit and harm in older adults, and the safety evidence has not caught up with consumer demand. An older adult who chooses to use either compound is best served by doing so with a clinician aware of the decision, baseline labs, a medication interaction review, and a plan for follow-up.

References

Other studies referenced in this article by general description (postmenopausal NMN trial, middle-aged/older adult NR crossover trial, AIM-HIGH niacin trial, and related mechanistic and pharmacology literature) could not be independently verified against their original publications for this draft. Their identifiers should be confirmed against PubMed or the original journal before being cited as authoritative sources in any clinical recommendation.